In various hereditary brain diseases, a mutated protein damages brain cells, resulting in health decline, limitations, and death. There is hope with some experimental therapies that can inhibit the production or toxic effects of these proteins. A consortium of organizations has received a €4.7 million grant from NWO to research and develop these treatments, with additional contributions of €0.8 million.

This includes Huntington’s disease, Spinocerebellar Ataxia (SCA) type 1, and SCA type 3. These hereditary diseases are caused by a similar DNA error, leading to the production of a diseased protein. The diseases can occur at a relatively young age and often rapidly lead to significant limitations.

Experimental Treatments

To date, there are no treatments that stop the diseases or slow the decline. Recent promising research has begun with experimental treatments, via spinal taps or a single administration in the brain, to inhibit the production of disease-causing proteins. But before these treatments can be safely and effectively applied, several important questions must be answered, such as:

When is the optimal time to start treatment?
Who will benefit from these therapies, and can we better predict the onset and progression of the disease for each patient individually?
Can we develop alternative therapeutic strategies to lower the harmful protein, preferably with a less invasive administration?
How can we assist gene carriers in making personal decisions about life planning and treatment options?
Collaborative Effort

To address all these questions in a coherent study (named CureQ), various organizations decided to collaborate. Researchers and physicians from various Dutch universities, different HBO programs, ethicists, biotechnology companies, patient associations, and the Proefdiervrij Foundation will work together in this study, aiming to enable a personalized approach and treatment for Huntington’s and SCAs.

CureQ Consortium

Org chart

Teams

Offices